Line Dufresne

Line Dufresne

Auto-generated profile, based on publicly available information

Line Dufresne

Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Royal Victoria Hospital, McGill University Health Centre, Montreal, Canada (Cole, Dufresne, Thanassoulis, and Sniderman)

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ASAllan D. Sniderman
Allan D. Sniderman
LDLine Dufresne
Line Dufresne
KPKarol M Pencina
Karol M Pencina
SBSelin Bilgic
Selin Bilgic
GTGeorge Thanassoulis
George Thanassoulis
MPMichael J Pencina
Michael J Pencina
Despite growing evidence that apolipoprotein B (apoB) is the most accurate marker of atherosclerotic cardiovascular disease (ASCVD) risk, its adoption in clinical practice has been low. This investigation sought to determine whether low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (HDL-C), and triglycerides are sufficient for routine cardiovascular care. A sample of 293 876 UK Biobank adults (age: 40–73 years, 42% men), free of cardiovascular disease, with a median follow-up for new-onset ASCVD of 11 years was included. Distribution of apoB at pre-specified levels of LDL-C, non-HDL-C, and triglycerides was examined graphically, and 10-year ASCVD event rates were compared for high vs. low apoB. Residuals of apoB were constructed after regressing apoB on LDL-C, non-HDL-C, and log-transformed triglycerides and used as predictors in a proportional hazards regression model for new-onset ASCVD adjusted for standard risk factors, including HDL-C. ApoB was highly correlated with LDL-C and non-HDL-C (Pearson’s r = .96, P < .001 for both) but less so with log triglycerides (r = .42, P < .001). However, apoB ranges necessary to capture 95% of all observations at pre-specified levels of LDL-C, non-HDL-C, or triglycerides were wide, spanning 85.8–108.8 md/dL when LDL-C 130 mg/dL, 88.3–112.4 mg/dL when non-HDL-C 160 mg/dL, and 67.8–147.4 md/dL when triglycerides 115 mg/dL. At these levels (±10 mg/dL), 10-year ASCVD rates for apoB above mean + 1 SD vs. below mean − 1 SD were 7.3 vs. 4.0 for LDL-C, 6.4 vs. 4.6 for non-HDL-C, and 7.0 vs. 4.6 for triglycerides (all P < .001). With 19 982 new-onset ASCVD events on follow-up, in the adjusted model, residual apoB remained statistically significant after accounting for LDL-C and HDL-C (hazard ratio 1.06, 95% confidence interval 1.0–1.07), after accounting for non-HDL-C and HDL-C (hazard ratio 1.04, 95% confidence interval 1.03–1.06), and after accounting for triglycerides and HDL-C (hazard ratio 1.13, 95% confidence interval 1.12–1.15). None of the residuals of LDL-C, non-HDL-C, or of log triglycerides remained significant when apoB was included in the model. High variability of apoB at individual levels of LDL-C, non-HDL-C, and triglycerides coupled with meaningful differences in 10-year ASCVD rates and significant residual information contained in apoB for prediction of new-onset ASCVD events demonstrate that LDL-C, non-HDL-C, and triglycerides are not adequate proxies for apoB in clinical care. Illustration of residual discordance and variance analysis of apoB and LDL-C/non-HDL-C in UK Biobank. LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non–high-density lipoprotein cholesterol; apoB, apolipoprotein B.

19 December 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ASAeron M. Small
Aeron M. Small
TYTa-Yu Yang
Ta-Yu Yang
SIShinsuke Itoh
Shinsuke Itoh
STSébastien Thériault
Sébastien Thériault
LDLine Dufresne
Line Dufresne
GTGeorge Thanassoulis
George Thanassoulis
Aortic stenosis (AS) is a common valvular heart disease and has no pharmacological therapies. We performed a multi-ancestry genome-wide association meta-analysis of 86,864 AS cases among 2,853,408 individuals, discovering 241 autosomal independent risk loci and 3 X chromosome risk loci. We additionally performed sex-stratified and ancestry-stratified genome-wide association studies (GWASs), identifying an additional 5 sex-specific risk loci, 11 risk loci in European ancestry individuals and 1 risk locus in African ancestry individuals. We also performed a transcriptome-wide association study using expression quantitative trait loci from human aortic valves, discovering 54 new genes for which genetically predicted expression influences the risk of AS. We then generated a new polygenic risk score for AS. Finally, we performed gene silencing experiments targeting biologically relevant genes identified by our GWAS. Silencing of CMKLR1 and LTBP4 in human valvular interstitial cells substantially decreased mineralization, implicating a role for polyunsaturated fatty acids and transforming growth factor β signaling in AS.

12 May 2023 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
DMDavide De Marco
Davide De Marco
KPKarol Pencina
Karol Pencina
MPMichael Pencina
Michael Pencina
LDLine Dufresne
Line Dufresne
GTGeorge Thanassoulis
George Thanassoulis
ASAllan D. Sniderman
Allan D. Sniderman

26 February 2026 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
SBSelin Bilgic
Selin Bilgic
KPKarol Pencina
Karol Pencina
MPMichael Pencina
Michael Pencina
LDLine Dufresne
Line Dufresne
GTGeorge Thanassoulis
George Thanassoulis
ASAllan D. Sniderman
Allan D. Sniderman
Conflicting results have been reported as to the relative importance of apolipoprotein A-1 (apoA-1) vs high-density lipoprotein cholesterol (HDL-C) as markers of atherosclerotic cardiovascular disease (ASCVD) risk. To compare the apoA-I and HDL-C as predictors of cardiovascular risk. Residual discordance analysis with Cox proportional hazard models comparing apoA-1 and HDL-C as markers of ASCVD risk was applied to a sample of 291,995 UK Biobank participants, followed for a median of 11 years. Interaction tests for the 2 markers and estimation of the effects of partitioning HDL-C into apoA-I, log-triglyceride, and the remaining residual were also performed. ApoA-1 and HDL-C had similar associations with ASCVD risk (hazard ratios [HRs] of 0.85, P value <.001 for both). The residual of HDL-C added significantly to the risk associated with apoA-1, as did the residual of apoA-1 to HDL-C. There was a statistically significant interaction between apoA-I and HDL-C (HR = 1.05, 95% CI: (1.04-1.06); P < .001). Decomposing HDL-C into the 3 components, apoA-I accounted for the largest portion of the effect, with an HR of 0.85 (95% CI: 0.83-0.86), with smaller effects for lnTG: 1.04 (95% CI: 1.02-1.06) and the residual of HDL-C: 0.98 (95% CI: 0.96-0.995). HDL-C and apoA-1 have associations of equivalent strength with ASCVD risk, with significant interaction modifying the effect of one by the other. Upon decomposition, apoA-I retained more of the effect of HDL-C as compared with log-triglycerides. While only observational, the results are consistent with the relation of HDL to risk not being determined by the concurrent level of triglyceride.

18 September 2026 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
JCJustine Cole
Justine Cole
LDLine Dufresne
Line Dufresne
PMPeter Paul MD
Peter Paul MD
MLMichel Langlois
Michel Langlois
GTGeorge Thanassoulis
George Thanassoulis
ASAllan D. Sniderman
Allan D. Sniderman
The American College of Cardiology (ACC)/American Heart Association (AHA) multisociety guidelines, state that discordance between apolipoprotein B (apoB) and Martin/Hopkins (MH) low-density lipoprotein cholesterol (LDL-C) is minimal at LDL-C targets of 100 and 70 mg/dL, citing studies that did not use the guideline's apoB targets. We aimed to quantify discordance at the recommended apoB targets, which correspond to values from uncited studies, and at population-equivalent values, and to determine the clinical significance of that discordance. Variance between LDL-C estimated by MH, modified-Sampson (mS), or Friedewald (F) and apoB was examined in the National Health and Nutrition Examination Survey (NHANES) database. Differences between achieving guideline targs of MH LDL-C, mS LDL-C, and F LDL-C vs guideline target levels of apoB (90, 70, and 55 mg/dL) or the percentile equivalent values of apoB in the untreated NHANES-based population (79, 58, and 46 mg/dL) were calculated. Clinical significance of discordance of MH-LDL-C was determined in the UK Biobank overall and at the 3 target levels of MH LDL-C. Significant discordance was present between LDL-C, however estimated, and apoB in the NHANES participants. Substantial differences between apoB and LDL-C at target levels were evident using guideline target values of apoB and even greater using population equivalent values of apoB. In the UK Biobank, residual discordance analysis demonstrated apoB was a more precise marker of cardiovascular risk than MH LDL-C overall and at MH LDL-C target levels of LDL-C of 100 and 70 mg/dL. This report identifies an apparent consequential error in the ACC/AHA multisociety guidelines and further supports the view that apoB should have at least equal priority to LDL-C and non-high-density lipoprotein cholesterol in routine clinical care.

16 July 2026 in Clinical Kidney Journal
Verified
Journal Article
Open access
ILIris Y Liu
Iris Y Liu
JHJenna Haverfield
Jenna Haverfield
EMElby MacKenzie
Elby MacKenzie
LDLine Dufresne
Line Dufresne
ARAimee K. Ryan
Aimee K. Ryan
IGIndra Gupta
Indra Gupta
Background: The tight junction family of claudin proteins regulates paracellular ion transport in the nephron and across epithelial and endothelial barriers throughout the body. Rare recessive variants in CLDN16 and CLDN19 cause familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), while common variants in CLDN2, CLDN10, and CLDN14 have been associated with kidney stones. Despite evidence that most claudin proteins are expressed within the nephron, their genetic contribution to kidney stone susceptibility has not been systematically explored. Methods: We analyzed 415 237 UK Biobank participants (9009 kidney stone cases and 406 228 controls) using exome sequencing and imputed genotype data spanning all 24 human CLDN genes. Single-variant association testing, gene burden analysis, and phenome-wide association studies were employed to identify novel associations. Results: Forty-three novel coding variant associations were identified through exome sequencing, including two CLDN16 variants: p.Gly57Arg (rs747654138; odds ratio [OR] = 42.2, P = 9.5 × 10−8) and p.Arg146His (rs772241737; OR = 60.5, P = 8.1 × 10−4). We replicated a known association with a CLDN19 variant, p.Arg200Gln (rs116804195; OR = 1.23, P = 2.6 × 10−4), which was also associated with decreased serum phosphate and increased alkaline phosphatase. We also identified 13 novel susceptibility loci within the imputed genotype dataset, including single nucleotide polymorphisms near CLDN2, CLDN10, CLDN11, CLDN18, and CLDN22–CLDN24 (all P < 0.00025), and confirmed a known CLDN14 association. Conclusions: Beyond established FHHNC genes, multiple CLDN family members harbor variants potentially influencing kidney stone risk, possibly through altered paracellular transport and mineral homeostasis. These findings expand kidney stone genetic architecture and suggest that claudin proteins merit further investigation in its pathogenesis.